Glanzmann Thrombasthenia (GT)
Gene or Region: ITGA2B
Reference Variant: G, 10bp indel (GACAGGTGAG)
Mutant Variant: C, - (deletion)
Affected Breeds: Thoroughbred, Standardbred, Oldenburg, Peruvian Paso, American Paint Horse, Appaloosa and American Quarter Horse
Research Confidence: Discovery - Findings require expanded validation
Explanation of Results: GT/GT = homozygous for Glanzmann Thrombasthenia, trait expressed GT/n = heterozygous for Glanzmann Thrombasthenia, trait possibly expressed n/n = no variant detected
General Description
Glanzmann Thrombasthenia (GT) is an inherited platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings. Two mutations in the gene encoding platelet glycoprotein IIb, Integrin Alpha-2B (ITGA2B), have been implicated in the GT condition. Although GT has been associated with a recessive mode of inheritance, heterozygous combinations from both variants have been implicated in GT cases. GT can be a differential diagnosis for horses with platelet-type bleeding, especially nasal bleeding not related to exercise or of unknown origin (not thrombocytopenic or from von Willebrand disease).
Genotype
G/G and/or GACAGGTGAG/GACAGGTGAG: No variants - Negative for the known genetic factors of Glanzmann Thrombasthenia (GT). Horse may still have Glanzmann Thrombasthenia (GT) signs from novel/unknown mutations.
G/C or GACAGGTGAG: One allele (at either locus) - Horse is a carrier for Glanzmann Thrombasthenia (GT). Selective breeding is advised as to not produce homozygous or compound heterozygous offspring.
G/C and GACAGGTGAG/- ; or C/C ; or -/-: Two alleles (at either locus) - Horse is affected by Glanzmann Thrombasthenia (GT). Please consult with your attending veterinarian about management for this condition.
References
Christopherson, P.W., van Santen, V.L., Livesey, L. and Boudreaux, M.K. (2007), A 10-Base-Pair Deletion in the Gene Encoding Platelet Glycoprotein IIb Associated with Glanzmann Thrombasthenia in a Horse. Journal of Veterinary Internal Medicine, 21: 196-198. https://doi.org/10.1111/j.1939-1676.2007.tb02947.x
Christopherson PW, Insalaco TA, Santen VL van, Livesey L, Bourne C, Boudreaux MK. Characterization of the cDNA Encoding αIIb and β3 in Normal Horses and Two Horses with Glanzmann Thrombasthenia. Veterinary Pathology. 2006;43(1):78-82. doi:10.1354/vp.43-1-78
More Horse Health
Equine Recurrent Uveitis Risk and Severity
Equine Recurrent Uveitis (ERU) is the most common cause of blindness in horses, affecting about 3-15% of the horse population worldwide. Characterized by episodes of inflammation of the middle layer of the eye, Equine Recurrent Uveitis in horses leads to the development of cataracts, glaucoma and eventually complete loss of vision.
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glycogen Branching Enzyme Deficiency
Glycogen Branching Enzyme Deficiency (GBED) is a lethal recessive disorder characterized by seizures, muscle weakness, respiratory failure, and death. Many affected foals do not make it full term and are aborted or stillborn. Carriers (gbed/n) have no known issues.
Hereditary Equine Regional Dermal Asthenia
Hereditary Equine Regional Dermal Asthenia (HERDA) is a degenerative skin disease that primarily affects the American Quarter Horse. Loose skin is often an early indication of the disease, and severe seromas, hematomas, ulcerations usually develop around 1.5 years of age. There is no cure, and the majority of affected animals have to be euthanized within 2-4 years.